Analysts Expect Blueprint Medicines Corp (NASDAQ:BPMC) to Post -$2.09 Earnings Per Share

Wall Street analysts expect Blueprint Medicines Corp (NASDAQ:BPMC) to post earnings per share (EPS) of ($2.09) for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Blueprint Medicines’ earnings. The lowest EPS estimate is ($2.16) and the highest is ($2.03). Blueprint Medicines reported earnings of ($2.04) per share in the same quarter last year, which would indicate a negative year over year growth rate of 2.5%. The firm is expected to report its next earnings report on Thursday, August 6th.

On average, analysts expect that Blueprint Medicines will report full-year earnings of ($8.40) per share for the current year, with EPS estimates ranging from ($8.77) to ($8.25). For the next financial year, analysts anticipate that the business will report earnings of ($6.80) per share, with EPS estimates ranging from ($8.29) to ($4.15). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Blueprint Medicines.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.08) by ($0.03). The business had revenue of $6.20 million during the quarter, compared to analysts’ expectations of $5.57 million. Blueprint Medicines had a negative net margin of 515.98% and a negative return on equity of 65.81%. Blueprint Medicines’s revenue for the quarter was up 749.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.98) EPS.

Several analysts have issued reports on the company. ValuEngine cut Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a report on Friday, May 1st. BMO Capital Markets increased their price target on Blueprint Medicines from $75.00 to $111.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Morgan Stanley decreased their target price on shares of Blueprint Medicines from $103.00 to $88.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. JMP Securities lowered their price target on Blueprint Medicines from $107.00 to $103.00 and set a “market outperform” rating for the company in a research report on Wednesday, April 29th. Finally, SVB Leerink dropped their price objective on shares of Blueprint Medicines from $125.00 to $105.00 and set an “outperform” rating for the company in a report on Wednesday, April 29th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $93.54.

In other Blueprint Medicines news, Director Nicholas Lydon sold 13,017 shares of Blueprint Medicines stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $80.29, for a total value of $1,045,134.93. Following the transaction, the director now owns 89,039 shares in the company, valued at approximately $7,148,941.31. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Jeffrey W. Albers sold 20,000 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $64.67, for a total value of $1,293,400.00. Following the sale, the chief executive officer now owns 161,434 shares of the company’s stock, valued at $10,439,936.78. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,217 shares of company stock worth $2,578,985. 3.81% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in the business. Bourgeon Capital Management LLC acquired a new position in shares of Blueprint Medicines in the 1st quarter valued at about $29,000. Advisor Group Holdings Inc. purchased a new stake in Blueprint Medicines during the first quarter worth approximately $32,000. NumerixS Investment Technologies Inc acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $46,000. Quantbot Technologies LP raised its stake in shares of Blueprint Medicines by 80.0% in the 4th quarter. Quantbot Technologies LP now owns 900 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 400 shares during the period. Finally, US Bancorp DE lifted its holdings in shares of Blueprint Medicines by 49.7% during the 4th quarter. US Bancorp DE now owns 1,430 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 475 shares in the last quarter. Institutional investors own 97.95% of the company’s stock.

Shares of Blueprint Medicines stock traded up $0.13 during trading hours on Friday, reaching $79.15. 265,494 shares of the company’s stock were exchanged, compared to its average volume of 767,645. The business has a fifty day moving average of $71.22 and a two-hundred day moving average of $67.59. The company has a quick ratio of 7.14, a current ratio of 7.17 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $4.29 billion, a P/E ratio of -10.65 and a beta of 1.09. Blueprint Medicines has a 1 year low of $43.29 and a 1 year high of $102.98.

About Blueprint Medicines

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Read More: What is a short straddle?

Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.